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The main culprit in the pathogenesis of ischemia/reperfusion (I/R) injury is the overproduction of reactive
oxygen species (ROS). Hydrogen peroxide (H2O2), the most abundant form of ROS produced during I/R,
causes inflammation, apoptosis and subsequent tissue damages. Here, we report H2O2-responsive
antioxidant nanoparticles formulated from copolyoxalate containing vanillyl alcohol (VA) (PVAX) as a
novel I/R-targeted nanotherapeutic agent. PVAX was designed to incorporate VA and H2O2-responsive
peroxalate ester linkages covalently in its backbone. PVAX nanoparticles therefore degradeand releaseVA,
which is able to reduce the generation of ROS, and exert anti-inflammatory and anti-apoptotic activity. In
hind-limb I/R and liver I/R models in mice, PVAX nanoparticles specifically reacted with overproduced
H2O2 and exerted highly potent anti-inflammatory and anti-apoptotic activities that reduced cellular
damages. Therefore, PVAX nanoparticles have tremendous potential as nanotherapeutic agents for I/R
injury and H2O2-associated diseases.
I
schemia/reperfusion (I/R) injury is cellular damage after reperfusion of previously ischemic tissues, and has
been associated with several pathophysiological conditions including coronary arterial disease and stroke
1–5.
Reperfusion of blood flow to the ischemic tissues results in a large generation of toxic reactive oxygen species
(ROS) and exacerbates initial tissue damages, which is the main culprit in the pathogenesis of I/R injury. In
particular, hydrogen peroxide (H2O2) induces release of pro-inflammatory cytokines and triggers apoptosis,
leading to the oxidative damage to tissues
6,7. Therefore, targeting H2O2 as a diagnostic marker and therapeutic
agent has tremendous potential.
Nanomaterials are being explored for many clinical applications in medicine
8. Because nanomaterials possess
greater permeability than other materials and could be formulated to respond to specific environmental factors,
such as pH or temperature
9,10, they hold great potential to be utilized in diagnosing and treating various medical
conditions.Inthisstudy,wedevelopedH2O2-responsivenanoparticlesasI/R-targeteddiagnosticandtherapeutic
agents and characterized their potential in animal models.
Results
We molecularlyengineeredPVAXtoexploitthetherapeutic activityofbioactive VAandtheabilityofperoxalate
ester bonds to rapidly react with H2O2. VA is an active pharmaceutical ingredient in Gastrodia elata Blume, an
herbal agent for brain ischemic injury and coronary heart diseases, and it exerts antioxidant, anti-inflammatory
and anti-nociceptive activity
11,12. PVAX was synthesized from a one-step polymerization of oxalyl chloride, VA
and 1,4-cyclohexanedimethanol (Fig. 1a). PVAX possesses peroxalate ester bonds and VA covalently incorpo-
rated in its backbone. The chemical structure of PVAX was confirmed by
1H NMR and its molecular weight was
determinedtobe,12,000 Dawithpolydispersityof1.6(Fig.1b).Despiteitsrapidhydrolysiskineticswithahalf-
life of ,36 h at pH 7.4 (Fig. 1c), PVAX was formulated into the solid nanoparticles under aqueous conditions
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SCIENTIFIC REPORTS | 3 : 2233 | DOI: 10.1038/srep02233 1because of its intrinsic hydrophobicity. PVAX nanoparticles were
round spheres and their hydrodynamic diameter was determined
to be ,500 nm (Fig. 1d and 1e).
PVAX was designed to release VA during its hydrolytic degrada-
tion under physiological conditions. In order to confirm the VA
release from PVAX, PVAX was incubated in H2Oa t3 7 uC for 3 days
and the supernatant was collected for
1H NMR. As shown in Fig. 1f,
PVAX underwent hydrolytic degradation to release VA. We then
investigated the release kinetics of VA from the PVAX nanoparticles
under the physiological conditions. PVAX nanoparticles (1 mg/mL)
released ,120 mg of VA during their hydrolytic degradation and
more than half of the VA was released within 24 h (Fig. 1g). The
rapid hydrolysis and VA release may provide considerable benefits
forthetreatment ofdiseases thatrequire thefastonset oftherapeutic
action, such as acute liver injury and vascular diseases.
PVAX contains peroxalate ester bonds in its backbone, which are
able to perform peroxalate chemiluminescence reaction in the pres-
ence of H2O2 and fluorophore. We therefore formulated chemi-
luminescent PVAX nanoparticles which encapsulate fluorophore
rubrene (Rb) and investigated whether chemiluminescent PVAX
nanoparticles could detect H2O2 by performing a three-component
peroxalatechemiluminescencereaction.PVAXnanoparticlesencap-
sulated with rubrene luminesced in the presence of H2O2, with a
linear relationship between the chemiluminescence intensity and
H2O2concentration (Fig. 2a). PVAX nanoparticles should also scav-
enge H2O2 because peroxalate ester bonds in PVAX will react with
H2O2 to generate dioxetanedione intermediates, which then should
instantaneously decompose into CO2.
We also found that PVAX nanoparticles dramatically reduced the
H2O2 concentration after 24 h in a dose-dependent manner,
demonstrating that peroxalate ester bonds in PVAX undergo
H2O2-mediated oxidation (Fig. 2b). Interestingly, VA also showed
moderate H2O2 scavenging activity. Therefore, the highly potent
H2O2 scavenging activity of PVAX nanoparticles is attributed to
the combined effects of peroxalate ester bonds and VA released.
The antioxidant activity of PVAX nanoparticles was investigated
by measuring the level of intracellular ROS in RAW 264.7 macro-
phages stimulated with phorbol-12-myristate-13-acetate (PMA)
using dichlorofluorescein-diacetate (DCFH-DA) as a marker of
intracellular oxidative stress
13–15. PMA treatment resulted in strong
dichlorofluorescein (DCF) fluorescence in cells, which is indicative
of oxidative stress in cells (Fig. 2c). VA (0.5 mM) slightly sup-
pressed ROS generation, but PVAX nanoparticles remarkably
inhibited the intracellular ROS generation. In order to further con-
firm the inhibitory effects of VA on ROS generation, we also pre-
pared polyoxalate (POX) which has only aliphatic peroxalate ester
bonds, but does not release VA. PVAX nanoparticles exhibited
significantly more reduction in PMA-induced ROS generation than
POX nanoparticles (Fig. 2d). These results demonstrate that the
PVAX nanoparticles exert strong antioxidant activities by first scav-
enging intracellular H2O2 and then releasing VA that inhibits the
further generation of ROS. In addition, cell toxicity study using
Figure 1 | Chemical characterization of H2O2-activatable PVAX nanoparticles. (a) A schematic diagram of PVAX nanoparticle 1 synthesis and
therapy for I/R. (b)
1H NMR spectrum of PVAX in CDCl3.
1H NMR in deuterated chloroform on a 400 MHz spectrometer: 7.0 , 7.3 (m, 3H, Ar),
5.3 (m,2 HO C H2-PhO-CH3), 4.1 , 4.2 (m, 4H, COOCH2CH), 3,8 (m, 3H, OCH3), 2.2 (m, 2H, C(CH2)3HO), 1.0 , 1.8 (m, 8H, Cyclic CH2).
(c) Hydrolysis kinetics of PVAX under physiological conditions, N 5 4/group. (d) A representative dynamic light scattering of PVAX nanoparticles
suspended in PBS. (e) A representative SEM image of empty PVAX nanoparticles. (f)
1H NMR spectrum of PVAX after hydrolysis of 2 days in D2O.
(g) Release kinetics of VA from PVAX.
www.nature.com/scientificreports
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biocompatibility (Fig. 2e).
We then evaluated the anti-inflammatory activities of PVAX
nanoparticles in cells stimulated with lipopolysaccharide (LPS) by
measuring the level of mRNA of genes related to inflammation. LPS
stimulationinducedremarkableexpressionofmRNAofpro-inflam-
matory mediators, such as inducible nitric oxide synthase (iNOS)
and cyclooxygenase-2 (COX-2) (Fig. 2f). VA (0.5 mM) suppressed
theexpressionofthesepro-inflammatorymediatorswithoutchanges
in the level of glyceraldehyde 3-phosphate dehydrogenase (GAP-
DH), an internal control. However, PVAX nanoparticles exhibited
the stronger inhibitory effect on the mRNA expression of iNOS and
COX-2 in the LPS-stimulated cells than free VA.
We then investigated anti-apoptotic activities of PVAX nanopar-
ticles in H2O2-stimulated cells (Fig. 2g). H2O2-stimulation activated
the apoptotic cascade in cells, as evidenced in rightward shift in
FITC-AnnexinVfluorescencebyflowcytometry,ingoodagreement
withtheliterature
16,17.Incontrast,PVAXnanoparticles exerted inhi-
bitory effects on H2O2-induced apoptosis in a dose-dependent man-
ner. A dose of 100 mg of PVAX nanoparticles significantly (,71%)
inhibitedH2O2-inducedapoptosis.Highlypotentanti-inflammatory
and anti-apoptotic activities of PVAX nanoparticles may be attrib-
uted to the combined effects of their antioxidant property and VA
release.Takentogether, PVAXnanoparticles demonstrate greatsyn-
ergistic therapeutic effects as a polymeric prodrug of VA as well as a
highly potent H2O2-scavenging agent.
Tofurtherextrapolateourinvitrofindings,weinvestigatedpoten-
tial of H2O2-responsive PVAX nanoparticles as I/R-targeted thera-
peutic agents using a mouse model of hind-limb I/R injury (Fig. 3a).
Initially, we tested H2O2-responsiveness of PVAX nanoparticles by
determining whether chemiluminescent PVAX nanoparticles could
image H2O2 generated endogenously during I/R. Ischemia was
induced for 45 minutes in both limbs and chemiluminescent
PVAX nanoparticles (PVAX/Rb) were directly injected just distal
to the ligation sites (50 mg PVAX/Rb per site). Left hind limb was
reperfused (I/R) but right hind-limb remained ligated (I). Chemi-
luminescent images were then captured at different time points. The
site of I/R injury exhibited an intense chemiluminescence light
emission lasting about 2 min after reperfusion demonstrating that
chemiluminescent PVAX nanoparticles are capable of imaging
endogenously generated H2O2 (Fig. 3b). Negligible chemilumin-
escentemissionwasobservedatthesiteofischemiaonly.Toconfirm
Figure 2 | Anti-oxidant and anti-inflammatory properties ofPVAX nanoparticles invitro. (a) Sensitivity ofchemiluminescent PVAX nanoparticles to
H2O2.(b)ScavengingofH2O2byPVAXnanoparticles.*,P,0.01versusControl;**,P,0.01versusVA,N54/group.(c)InhibitionofROSgeneration
by PVAX in PMA-stimulated macrophages. (d) Comparison in antioxidant activity of PVAX and POX. (e) Cytotoxicity of PVAX nanoparticles
determined by MTT assay. VA 5 vanillyl alcohol. N 5 4/group. (f) Anti-inflammatory activity of PVAX in LPS-stimulated macrophages. (g) Anti-
apoptotic property of PVAX in H2O2-stimulated macrophages.
www.nature.com/scientificreports
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enzyme catalase was injected prior to the injection of PVAX nano-
particles. Pre-administration of catalase almost completely inhibited
chemiluminescenceemissionatthesiteofI/Rinjury(Fig.3c),further
demonstratingthatPVAXnanoparticlesspecificallydetectH2O2.To
ourbestunderstanding,thisisthefirststudytoreporttheimagingof
endogenously generated H2O2 in I/R injury.
To test the therapeutic potential of PVAX nanoparticles for I/R
injury,weinjectedPVAXnanoparticlesinthegastrocnemiusmuscle
after hind-limb I/R. Since I/R is known to induce apoptosis and
cellular damage, we examined the ability of PVAX nanoparticles to
inhibittheactivationofpolyADPribosepolymerase-1(PARP-1)and
caspase-3, both critical enzymes involved in apoptosis
18–20. Since VA
has been shown to have antioxidant and anti-inflammatory effect by
itself, we injected the equivalent amount of VA (by weight, 1 VA 5
10 PVAX) in a contralateral leg for comparison with PVAX. After I/
R, there was significant activation of PARP-1 and caspase-3 (Fig. 3d
and 3e). Treatment of PVAX nanoparticles showed significant
inhibition of PARP-1 and caspase-3 activation by I/R in a dose
dependent manner. In comparison, VA alone at the equivalent
amounts contained in PVAX was able to modestly inhibit PARP-1
andcaspase-3activationonlyatthehighestdose.Furthermore,treat-
ment of PVAX nanoparticles demonstrated significant decrease in
apoptotic myocytes after I/R compared to VA alone(Fig. 4a and 4b).
There was also significant attenuation of various inflammation mar-
kers, such as tumor necrosis factor-alpha (TNF-a), monocyte che-
motactic protein-1 (MCP-1), and interleukin -1b (IL-1b), and, after
I/RinPVAXgroupcomparedtotheI/R1vehiclegroup(Fig.4c–4f).
VA alone showed no significant suppression of these inflammatory
markers. In addition, histological analysis showed that significant
muscle damage induced by I/R injury was effectively blocked by
PVAX nanoparticles (Fig. 4g). The higher therapeutic effects of
PVAX than VA can be explained by the synergistic effects of
H2O2-scavening peroxalate ester bonds and antioxidant and
anti-inflammatory effect of VA. This study provides proof-of-con-
cept that molecularly engineered PVAX nanoparticles are able to
scavenge and image overproduced H2O2 and serve as I/R targeted
therapeutic agents.
InordertofurtherdemonstratethetherapeuticpotentialofPVAX
nanoparticles in another clinically relevant setting, we used a mouse
model of hepatic I/R. Hepatic I/R is a feature of many clinically
important scenarios including liver transplantation
21,22. In this
model, PVAX (3 mg/kg) nanoparticles were injected intraperitone-
ally (i.p.) one hour prior to performing I/R in liver and again given
justafterreperfusiontoevaluatetheirtherapeuticpotential.After1 h
of ischemia and 6 h of reperfusion, a dramatic increase in the serum
alanine transaminase (ALT) activity, a marker of liver damage, was
observed in a vehicle-treated group, compared with sham-operated
controls (Fig. 5a). PVAX therapy significantly attenuated the serum
ALT elevations induced by I/R. In addition, I/R markedly increased
the PARP-1 and caspase activities in the liver, which was prevented
by PVAX (Fig. 5b and 5c). Treatment with PVAX nanoparticles was
also effective in decreasing apoptosis in hepatocytes after I/R com-
pared to the saline I/R group (Fig. 5d and 5e). Furthermore,
I/R significantly increased the mRNA expression of the proinflam-
matory cytokine TNF-a, MCP-1 and IL-1b (Fig. 5f and 5g). The
I/R-induced acute hepatic proinflammatory responses, likely orche-
strated by activated Kupffer and endothelial cells, were significantly
attenuated byPVAXnanoparticles. Based on these findings, we con-
clude that PVAX nanoparticles have potential to be used as effective
I/R-targeted nano-therapeutic agents and intrinsic antioxidant and
anti-inflammatory properties of PVAX may further contribute to
their overall beneficial effect during I/R injury.
Finally,totestthesafetyprofileofPVAX, weadministered100 mg
ofPVAX nanoparticles dailyfor7 daysin mice.Serum testsforrenal
and hepatic function showed no significant abnormalities after 7
days(Fig.6a).Inaddition,therewasnoobvioushistologicalevidence
of accumulated toxicity in the different organs associated with
Figure 3 | Bioimagingandapoptosisinhind-limbI/RmodelafterPVAXinvivo. (a)Aschematicdiagramofhind-limbischemia/reperfusionprotocol.
(b) In vivo imaging of PVAX/Rb after I/R in mouse hind-limbs. Reperfusion at different time points as indicated. Acquisition time 5 30 sec/image.
(c)InvivoimagingofPVAX/Rbwithandwithoutcatalase.(d-e)Quantificationofcaspase-3activities(d)andPARP-1activity(e)afterI/Rwithdifferent
concentrations of PVAX in gastrocnemius muscles. *,P, 0.05 vs Sham; {,P, 0.05 vs Veh 1 IR. N 5 4–6/group.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 2233 | DOI: 10.1038/srep02233 4administration of PVAX nanoparticles for 7 days (Fig. 6b), dem-
onstrating the excellent in vivo biocompatibility of PVAX.
Discussion
Tissue damage is the most important determinant of morbidity and
mortality after conditions associated with I/R injuries, such as
myocardial infarction, vascular thromboembolic events, post
cardiovascular surgery, transplant surgery, and post traumatic injur-
ies
2,5,23,24. Therefore, limiting cellular death is paramount for favor-
able outcomes in these conditions. Particularly, suppression of ROS
overproduction during I/R using various antioxidants have been
shown to effectively block the deleterious effects of ROS, such as
apoptosis, in experimental settings in vitro and in vivo
4,25. How-
ever, the beneficial effects of antioxidant therapy in human clinical
studieshavebeendisappointingduemainlytonon-specificsuppres-
sion of ROS in the body
26,27. I/R-specific drug formulations would
allow targeted release of drugs into specific areas or tissues that are
undergoing a pathological process, leading to the enhanced thera-
peutic efficacy as well as decrease in related side effects. Therefore,
H2O2-responsive PVAX nanoparticles may be able to serve as I/R
targeted nanotherapeutic agents.
Ideal targeted drug delivery system would have combined target
specificity with stimuli responsiveness to enhance the effects of the
system
10. Several such drug delivery systems have been generated
that are responsive to pH, temperature, magnetic field, and concen-
trationsofelectrolytesorglucose
9,10.PVAXnanoparticlesarethefirst
nanotherapeuticsystemthatisshowninanimalmodelstoeffectively
treat tissues undergoing I/R injury by targeting endogenously gen-
erated H2O2 with high sensitivity and specificity.
In summary, we present novel I/R targeted nano-therapeutic
agents based on molecularly engineered PVAX nanoparticles, which
are sensitive and specific to H2O2. PVAX nanoparticles exhibit sig-
nificant intrinsicantioxidant, anti-inflammatory, andanti-apoptotic
activitiesbothinvitroandinvivomodelsofI/Rinjury.Weanticipate
enormous potential of multifunctional PVAX nanoparticles for the
H2O2-associated diseases, such as cardiovascular and neurovascular
diseases.
Methods
PVAX synthesis. 1,4-Cyclohexanedimethanol (21.96 mmol) and 4-vanillyl alcohol
(5.49 mmol) were dissolved in 20 mL of dry tetrahydrofuran (THF), under nitrogen,
to which triethylamine (60 mmol) was added dropwise at 4uC. Oxalyl chloride
(27.45 mmol) in 25 mL of dry THF was added to the mixture dropwise at 4uC. The
reaction was continued at room temperature for 6 h under nitrogen atmosphere and
the resulting polymers were obtained through the extraction using dichloromethane
andisolationbyprecipitatingincoldhexane.Thechemicalstructureofpolymerswas
Figure 4 | Celldeathandinflammationinhind-limbI/RmodelafterPVAXinvivo. (a)RepresentativeTUNELstainingofgastrocnemius musclesafter
I/RwithandwithoutPVAX.(b)QuantificationofapoptosisrateingastrocnemusmusclesafterI/RwithandwithoutPVAX.*,P,0.05versusSham;{,P
,0.05versusVeh1I/R.N54–6/group.(c)mRNAlevelsoffactorsassociatedwithinflammationafterI/RwithdifferentconcentrationsofPVAX.(d–f)
Quantification of TNF-a (d), IL-1b (e), and MCP-1 (f) mRNA levels after I/R with different concentrations of PVAX in HL I/R model. *,P, 0.05 vs
Sham; {,P, 0.05 vs Veh 1 IR. N 5 4-6/group. (g) Haematoxylin and eosin-stained histological sections of gastrocnemius muscle showed less damage
and less apparent leucocyte infiltration in muscles in PVAX treated mice after I/R.
www.nature.com/scientificreports
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1H NMR spectrometer and their molecular weight was
determined using a gel permeation chromatography (GPC).
Particle preparation and characterization. Fifty milligrams of PVAX dissolved in
500 mL of DCM was added to 5 mL of 10% poly-vinyl alcohol (PVA) solution. The
mixture was sonicated using a sonicator (Fisher Scientific, Sonic Dismembrator 500)
for 30 sec and a homogenizer (PRO Scientific, PRO 200) for 2 min to form a fine oil/
water emulsion. The emulsion was added into 20 mL PVA 1% solution and further
homogenized for 1 min. The remaining solvent was removed using a rotary
evaporator. PVAX nanoparticles wereobtainedbycentrifugingat11,000 gfor 5 min
at4uC, washing with deionized water twiceand lyophilizing the recovered pellet. The
morphology and size of PVAX nanoparticles were observed by a scanning electron
microscopy (SEM, S-3000N, Hitachi, Japan) with accelerating voltage of 10 Kv. The
hydrodynamic size of PVAX nanoparticles was determined using a particle analyzer
(ELS-8000, Photal Otsuka Electronics, Japan).
ReleasekineticsofvanillylalcoholfromPVAXnanoparticles.PVAXnanoparticles
(5 mg) were added into 5 mL of phosphate buffer solution (pH 7.4) and the particles
suspension was incubated at 37uC with mechanical stirring. At appropriate intervals,
the solution was centrifuged at 20003g for 20 sec and the 1 mL aliquot of
supernatant was taken and replaced with an equal volume of fresh phosphate buffer
solution.Theconcentrationofvanillylalcoholinthesupernatantwasmeasuredusing
a UV spectrometer (S-3100, Scinco, Korea) and the release kinetics was determined
by comparing the concentrations of vanillyl alcohol standard solutions.
Cytotoxicity assay and detection of H2O2. 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay was performed to evaluate the
cytotoxicity of PVAX nanoparticles. Mouse macrophage RAW 264.7 cells were
culturedatadensityof1310
6 cells/wellina24wellplatecontaining1 mLofculture
medium for 24 h. Cells were treated with various amounts of nanoparticles and
incubated for 24 h. Each well was given 20 mL of MTT solution and were incubated
for 4 h. Two hundred microlitters of dimethyl sulfoxide (DMSO) was added to each
well to dissolve the resulting formazan crystals. After 30 min of incubation, the
absorbance at 570 nm was measured using a microplate reader (E-Max, Molecular
Device Co. US). The cell viability was obtained by comparing the absorbance of
nanoparticles-treated cells to that of control cells.
Flow cytometry. RAW 264.7 cells (1 3 10
6 cells) were cultured for 24 h. Cells were
treated with vanillyl alcohol and PVAX nanoparticles for 4 h. Phorbol-12-myristate-
13-acetate (PMA, 0.5 mg) was given to cells for the generation of reactive oxygen
species and 20 h later cells were treated with DCFH-DA. Cells were also treated with
100 mMofH 2O2for4 htoinduceapoptosisandtreatedwithAnnexin-Vlabeledwith
FITC for 15 min. Flow cytometry was performed with a Flow Cytometry Caliber
(Becton Dickinson, US).
Reverse transcription-polymerase chain reaction (RT-PCR). The RAW 264.7 cells
were plated at a density of 2 3 10
5 in 24 well tissue culture plates. The cells were
pretreatedwith0.5 mMvanillylalcoholandavariousamountofPVAXnanoparticles
for 24 h and then treated with 1 mL of LPS (1 mg/mL) for 12 h. Total cellular RNA
was isolated using 1 mL of TRIzol (Invitrogen, Life Technologies Co, Groningen,
Netherlands) according to the manufacturer’s instructions. One microgram of total
RNA was reverse-transcribed into cDNA using oligo (dT) primer (Invitrogen), 5X
First Strand buffer (Invitrogen), dNTP (Gibco), RNase inhibitor (Invitrogen),
SuperScriptII(Invitrogen),andRNaseHreversetranscriptase(Invitrogen).PCRwas
Figure 5 | I/R-specific therapy using PVAX in hepatic I/R model in vivo. (a) Serum ALT level after 60 min ischemia and 6 h reperfusion with
or without i.p. administration of PVAX. *,P, 0.05 versus Sham; {,P, 0.05 versus Veh 1 I/R. N 5 4–6/group. (b–c) Quantification of caspase-3
activities(b)andPARP-1activity(c)oftheliverafterI/RwithandwithoutPVAX.*,P,0.05versusSham;{,P,0.05versusVeh1I/R.N54–6/group.
(d) Representative TUNEL staining of liver after I/R with and without PVAX. (e) Quantification of apoptosis rate in liver after I/R with and without
PVAX. *,P, 0.05 versus Sham; {,P, 0.05 versus Veh 1 I/R. N 5 4–6/group. (f) Semi-quantitative PCR of mRNA levels of factors associated with
inflammation after i.p. administration of PVAX after hepatic I/R. (g) Quantification of TNF-a, MCP-1 andIL-1b mRNA levels after I/Rwith or without
PVAX in hepatic I/R model. *,P, 0.05 versus Sham; {,P, 0.05 versus Veh 1 I/R. N 5 4–6/group.
www.nature.com/scientificreports
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GAPDH(theinternalstandard)geneexpressions.ThePCRprimersusedinthisstudy
arelistedbelow:senseiNOS,59-AATGGCAACATCAGGTCGGCCATCACT-39,
anti-sense iNOS, 59-GCT GTG TGT CAC AGA AGT CTC GAA CTC-39; sense
COX-2,59-GGAGAGACTATCAAGATAGT-39,anti-senseCOX-2,59-ATGGTC
AGT-AGACTTTTACA-39;senseGAPDH,59-TGAACGGGAAGCTCACTGG-
39,anti-sense GAPDH, 59-TCC ACC ACC CTG TTG CTG TA-39.The PCR primers
used for animal tissues are listed below: sense TNF-a,5 9-CCT CAG CCT CTT CTC
CTT CCT-39, anti-sense TNF-a,5 9-GGT GTG GGT GAG GAG CA-3; sense IL-1 b,
59-CTG AAA GCT CTC CAC CTC-39, anti-sense IL-1 b reverse, 59-TGC TGA TGT
ACC AGT TGG GG-39; sense MCP-1 forward, 59-CCC CAC TCA CCT GCT GCT
ACT-39, anti-sense MCP-1 reverse, 59-GGC ATC ACA GTC CGA GTC ACA -39;
sense18Sforward,59-GTTATGGTTCCTTTGTCGCTCGCTC-39,anti-sense18S
reverse, 59- TCG GCC CGA GGT TAT CTA GAG TCA C-39. After amplification,
portionsofthePCRreactions wereelectrophoresedon2%agarosegel,and visualized
under UV after ethidium bromide staining.
Animal surgeries. Hind limb I/R surgeries were performed in 15–16 week old male
mice (Charles River Laboratory, Wilmington, MA). After mice were anaesthetized,
femoral artery was identified and tied around a specialized 30G-catheter with a 7-0
silk suture. The animal remained under anesthesia for a specified duration of
ischemia. Reperfusion was achieved by cutting the suture and re-establishing arterial
blood flow. Sham operated mice underwent the same procedure without femoral
artery occlusion/reperfusion. Mice were sacrificed and analyzed at 2 days for
biochemical/molecular studies, and at 2 weeks for histological analysis.
Hepatic I/R surgeries were done in 10–12 week-old male mice (Charles River
Laboratory, Wilmington, MA). One hour prior to anesthesia, PVAX group mice
received 50 ml of PVAX nanoparticle through intraperitoneal route. Mice in
saline group received same volume of normal saline. After one hour, all mice were
anaesthetized with intraperitoneal injection of mixed solution of Ketamine and
Xylazine (851 ratio). Midline incision was performed for laparotomy. After
identifying the portal triad and biliary tree, the main trunk of hepatic artery and
portal vein were clamped with vascular clip except for the vasculatures to the right
lowerlobetoachieveischemicinjurytoapproximately70%oftheliver.60minutesof
ischemic time was allowed in I/R group mice. No vascular clamp was done for Sham
group mice. After one hour, reperfusion was achieved by releasing the vascular clip.
At that moment, additional 50 ml of PVAX nanoparticle was given to PVAX group,
and same amount of saline was administered for Saline group. Then the midline
incision was closed with 5-0 black silk suture. Half of the mice in each group were
sacrificed at 6 hours for inflammatory activities (TNF-a,I L - 1 b, and MCP-1) and
serum ALT measurements, and the rest were sacrificed at 24 hours for apoptotic
activities (caspase-3, PARP-1). All experimental procedures were approved by the
Institutional Animal Care and Use Committee of Beth Israel Deaconess Medical
Center.
Chemiluminescenceimaging.Invivobioluminescenceimagingwascarriedoutwith
a Xenogen IVIS 200 imaging system (Caliper LS, Hopkinton, MA). Images and
measurementsofluminescentsignalswereacquiredandanalyzedusingLivingImage
software. Balb/c mice (Orient Bio, Korea) were anesthetized using 1–3% isoflurane,
and placed onto the warmed stage inside the camera box. The animals received
continuous exposure to 1–2% isoflurane to sustain sedation during imaging. All
experiment procedures were performed with the approval of Chonbuk National
University Animal Care Committee.
Figure 6 | Safety profiles of PVAX. (a) Creatinine and ALT level after daily i.p. administration of PVAX (100 mg/day) for 7 days. NS 5 not significant.
N 5 4/group. (b) Representative Hematoxylin and Eosin (H&E)-stained tissue sections of various organs after PVAX. PVAX was administered i.p. at
100 mg/day for 7 days. N 5 3/group.
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software (GraphPad Software Inc., La Jolla, CA). Statistical analysis was carried out
using the one-way analysis of variance (ANOVA) and Bonferroni’s tests for post hoc
differences between group means. Statistical significance was defined as P , 0.05.
Results are presented as mean 6 the standard error of the mean (SEM).
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